Shares of Zogenix Inc. (NASDAQ:ZGNX) climbed 20.7 percent to close at $55.90 on Thursday after a second pivotal study of ZX-008 (fenfluramine) showed the drug maintaining its ability to diminish seizures among young people with rare and severe epilepsy type Dravet syndrome, even when added to standard-of-care therapy. Participants achieved a 54.7 percent greater reduction in mean monthly convulsive seizures vs. placebo during the phase III trial and remained free of heart valve damage, easing safety concerns raised by fenfluramine in an earlier chapter of its use. (See BioWorld, Oct. 2, 2017.)